Despite advancements in lupus management over the past two decades, infection remains a significant cause of morbidity and mortality among patients with systemic lupus erythematosus (SLE). 1 2 Various ...

Bone involvement is a common cause of morbidity and disability in systemic lupus erythematosus (SLE). 1 This is both a consequence of the disease itself and treatments, including steroids.2 As ...

Systemic lupus erythematosus (SLE) is a clinically and immunologically heterogeneous autoimmune disease that can be challenging to diagnose, especially in its early stages. Although developed in the ...

Clinicians remain believers in B-cell depletion despite the failure of rituximab in the EXPLORER, LUNAR, and BELONG clinical trials. 1–3 Additional studies suggested that the B-cell depletion that ...

The British Isles Lupus Assessment Group (BILAG)-2004 index is a comprehensive disease activity instrument for systemic lupus erythematosus (SLE). 1 Its key advantages are the ability to capture rare ...

Background/ Purpose We recently showed that in SLE, IL-4 suppressed the development of interferon-beta (IFNβ) and TLR7-stimulated T-bet + double negative 2 (DN2) B cells. Here we investigate the ...

Background/ Purpose Systemic lupus erythematosus (SLE) is an autoimmune disease with heterogeneous manifestations across patient populations. Although real-word evidence data on SLE exists via SLE ...

Conclusions Voclosporin was well-tolerated over three years of treatment. The significant reductions in proteinuria initially achieved in AURORA 1 were maintained throughout AURORA 2 and more patients ...

Introduction SLE is an autoimmune disease with an increased risk for poor outcomes in pregnancy. In 2020, ACR specified several recommendations to assist clinicians in preparing patients with SLE and ...

Background Lupus is a complex autoimmune disease characterized by loss of self-tolerance, leading to dysregulated functions of T and B cells. Broadly increased glucose metabolism has been reported in ...

Background/ Purpose Nephritis is one of the most severe manifestations in lupus, affecting 40–70% of patients. Though immune targeted therapies have improved, a significant number of patients ...

LBP1 Interim results of an open-label, multicentre, Phase 1/2 study to assess YTB323 (rapcabtagene autoleucel), a CAR T-cell therapy, for severe refractory systemic lupus erythematosus ...